Experimental drug targets rare skin cancer in First-Ever human test
NCT ID NCT07213882
Summary
This is the first-ever human trial of an experimental antibody called DT-7012 for patients with advanced cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. The study aims to find a safe dose and check for early signs that the drug might help control the disease in 30 adults whose cancer has returned or hasn't responded to at least two prior treatments. Researchers will closely monitor side effects and how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.